Pivoting globally as local pressures mount

A global reset after local setbacks

Zai Lab is navigating a difficult transition period. In early 2026, the company reported a 10% year-over-year decline in total product revenue. The primary cause was a steep 39% drop in sales for its top drug, ZEJULA, as generic competition altered hospital buying patterns in China. Management has cautioned that top-line pressure will likely continue through the rest of the year, setting expectations for a return to meaningful growth only in 2027.

To counter this decline, the company points to its diversified portfolio and a strategic pivot toward global markets. New products like XACDURO and NUZYRA have grown rapidly, and the recent launch of KarXT for schizophrenia adds another potential revenue stream. Most importantly, management has set clear timelines for Zoci, an antibody drug conjugate for small cell lung cancer. The company expects to finish Phase III enrollment in early 2027 and file for U.S. accelerated approval later that year. This global ambition could significantly alter the company's valuation if successful.

The bear case remains focused on the immediate cash flow problem. The rapid erosion of ZEJULA sales removes the company's primary profit engine just as it needs capital for global trials. While XACDURO is growing, severe supply constraints will limit its contribution until local manufacturing comes online. Furthermore, China's National Reimbursement Drug List imposes strict price controls, as seen when VYVGART took a price cut after renewal. This makes achieving near-term profitability much harder.

Finn's scores reflect a cautious view. Growth and sentiment hold promise based on the pipeline, but low valuation and performance scores show the market requires proof that the new products can outpace the decay of the old ones. The critical tests ahead are the easing of XACDURO supply issues and the timely progress of the Zoci clinical trials.

License locally, develop globally

Historically, Zai Lab has operated by licensing promising clinical-stage drugs from global pharmaceutical companies. The company runs the necessary local trials, secures regulatory approval from Chinese authorities, and builds the commercial infrastructure to sell the drugs in Greater China. This model allowed Zai Lab to build a broad portfolio quickly without the extreme early-stage risks of pure drug discovery.

Revenue generation is highly dependent on securing a spot on China's National Reimbursement Drug List. Being on the list dramatically increases the number of patients who can afford a drug, but it almost always requires the manufacturer to accept severe price cuts. Balancing this volume-for-price tradeoff is central to the company's financial health. The recent price adjustment for VYVGART illustrates this constant pressure.

The business is now evolving. Instead of relying solely on the Chinese market, Zai Lab is investing heavily in global clinical trials for its own innovative assets, particularly in oncology. Developing drugs for a worldwide market requires significantly more capital but offers far larger revenue potential and escapes the specific pricing constraints of the Chinese healthcare system. Proving they can successfully execute a U.S. regulatory submission is the next major hurdle.

A shifting revenue mix

First quarter product mix

Zai Lab operates as a single segment. Based on Q1 2026 data, the revenue base remains highly concentrated, with ZEJULA still accounting for 31.4% of total product sales.

What could go wrong

In one breath